Qualigen Therapeutics Stock Today
| QLGN Stock | USD 0.29 0.01 3.33% |
Performance0 of 100
| Odds Of DistressOver 85
|
Qualigen Therapeutics is selling at 0.29 as of the 28th of April 2024; that is -3.33 percent decrease since the beginning of the trading day. The stock's open price was 0.3. Qualigen Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Qualigen Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of March 2024 and ending today, the 28th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of June 2015 | Category Healthcare | Classification Health Care |
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. Qualigen Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 6.31 M outstanding shares of which 49.41 K shares are at this time shorted by private and institutional investors with about 0.55 trading days to cover. More on Qualigen Therapeutics
Moving against Qualigen Stock
| 0.74 | HCWB | HCW Biologics | PairCorr |
| 0.7 | KRYS | Krystal Biotech Financial Report 13th of May 2024 | PairCorr |
| 0.67 | ELYM | Eliem Therapeutics Upward Rally | PairCorr |
| 0.65 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.61 | ACB | Aurora Cannabis Sell-off Trend | PairCorr |
| 0.54 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
| 0.5 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Report 7th of May 2024
Qualigen Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Qualigen Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Qualigen Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| COO, President | Michael Poirier | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Qualigen Therapeutics report their recommendations after researching Qualigen Therapeutics' financial statements, talking to executives and customers, or listening in on Qualigen Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Qualigen Therapeutics. The Qualigen consensus assessment is calculated by taking the average forecast from all of the analysts covering Qualigen Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Qualigen Therapeutics' liquidity, profitability, solvency, and operating efficiency, Qualigen Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Qualigen Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Qualigen Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Qualigen Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Qualigen Therapeutics' financial leverage. It provides some insight into what part of Qualigen Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Qualigen Therapeutics (QLGN) is traded on NASDAQ Exchange in USA. It is located in 2042 Corte Del Nogal, Carlsbad, CA, United States, 92011 and employs 4 people. Qualigen Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.83 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Qualigen Therapeutics's market, we take the total number of its shares issued and multiply it by Qualigen Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Qualigen Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.31 M outstanding shares of which 49.41 K shares are at this time shorted by private and institutional investors with about 0.55 trading days to cover.
Qualigen Therapeutics currently holds about 6.62 M in cash with (10.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Qualigen Therapeutics Probability Of Bankruptcy
Ownership AllocationQualigen Therapeutics has a total of 6.31 Million outstanding shares. Qualigen Therapeutics holds 11.51 pct. of its outstanding shares held by insiders and 2.61 pct. owned by third-party entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Qualigen Ownership Details
Qualigen Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Qualigen Therapeutics jumping above the current price in 90 days from now is roughly 97.0%. The Qualigen Therapeutics probability density function shows the probability of Qualigen Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.4787 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Qualigen Therapeutics will likely underperform. Additionally, qualigen Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Qualigen Therapeutics to move above the current price in 90 days from now is roughly 97.0 (This Qualigen Therapeutics probability density function shows the probability of Qualigen Stock to fall within a particular range of prices over 90 days) .
Qualigen Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Qualigen Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Qualigen Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Qualigen Therapeutics' value.| Instituion | Recorded On | Shares | |
| Ica Group Wealth Management, Llc | 2023-12-31 | 245 | |
| Ubs Group Ag | 2023-12-31 | 102 | |
| Wells Fargo & Co | 2023-12-31 | 39.0 | |
| Archer Investment Corporation | 2023-12-31 | 16.0 | |
| Royal Bank Of Canada | 2023-12-31 | 4.0 | |
| Fmr Inc | 2023-12-31 | 2.0 | |
| Meitav Dash Investments Ltd | 2023-09-30 | 0.0 | |
| Geode Capital Management, Llc | 2023-12-31 | 41.9 K | |
| Blackrock Inc | 2023-12-31 | 25.8 K | |
| Vanguard Group Inc | 2023-12-31 | 22.8 K | |
| Northern Trust Corp | 2023-12-31 | 11.9 K |
Qualigen Therapeutics Historical Income Statement
Qualigen Therapeutics Income Statement is one of the three primary financial statements used for reporting Qualigen's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Qualigen Therapeutics revenue and expense. Qualigen Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Qualigen Therapeutics' Depreciation And Amortization is very stable compared to the past year. As of the 28th of April 2024, Interest Expense is likely to grow to about 1.6 M, while Interest Income is likely to drop about 86.2 K. View More FundamentalsQualigen Stock Against Markets
Picking the right benchmark for Qualigen Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Qualigen Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Qualigen Therapeutics is critical whether you are bullish or bearish towards Qualigen Therapeutics at a given time. Please also check how Qualigen Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Qualigen Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Economic Indicators Now
Economic IndicatorsTop statistical indicators that provide insights into how an economy is performing |
| All Next | Launch Module |
Qualigen Therapeutics Corporate Management
Elected by the shareholders, the Qualigen Therapeutics' board of directors comprises two types of representatives: Qualigen Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Qualigen. The board's role is to monitor Qualigen Therapeutics' management team and ensure that shareholders' interests are well served. Qualigen Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Qualigen Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA | Senior Officer | Profile | |
| Amy Broidrick | Chief Pres | Profile | |
| Wajdi AbdulAhad | VP Officer | Profile | |
| Shishir Sinha | Corp COO | Profile |
How to buy Qualigen Stock?
Before investing in Qualigen Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Qualigen Therapeutics. To buy Qualigen Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Qualigen Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Qualigen Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Qualigen Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Qualigen Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Qualigen Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Qualigen Stock please use our How to Invest in Qualigen Therapeutics guide.
Already Invested in Qualigen Therapeutics?
The danger of trading Qualigen Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Qualigen Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Qualigen Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Qualigen Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Qualigen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Qualigen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Qualigen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Qualigen Therapeutics Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.Note that the Qualigen Therapeutics information on this page should be used as a complementary analysis to other Qualigen Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Qualigen Stock analysis
When running Qualigen Therapeutics' price analysis, check to measure Qualigen Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Qualigen Therapeutics is operating at the current time. Most of Qualigen Therapeutics' value examination focuses on studying past and present price action to predict the probability of Qualigen Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Qualigen Therapeutics' price. Additionally, you may evaluate how the addition of Qualigen Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Qualigen Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Revenue Per Share 1.034 | Quarterly Revenue Growth 0.137 | Return On Assets (0.67) | Return On Equity (3.74) |
The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qualigen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.